Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

Azathioprine may be an effective treatment for severe hair loss.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This study found that immunotherapy with DNCB or DPCP showed better therapeutic effects than intralesional triamcinolone acetonide for patients with bald areas greater than 50 cm², including alopecia totalis and universalis.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

In this case study, the researchers investigated a 44-year-old woman who developed rapidly progressing alopecia universalis after receiving a COVID-19 vaccine, and reviewed existing literature to explore potential links between COVID-19 vaccines and autoimmune hair loss conditions like alopecia areata and universalis.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

This study found that early-onset patients with alopecia universalis or a family history of alopecia areata showed worse prognosis compared to those with late-onset.

This case study reports that tofacitinib led to remission of psoriasis but did not improve alopecia universalis in one patient, suggesting varied responses in treating such conditions.

This study found that superficial cryotherapy significantly increased hair density and thickness in treated eyebrows compared to untreated controls after 5 months in patients with alopecia areata.

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.

This case report describes irreversible alopecia universalis following discontinuation of Peg-IFN/RBV treatment for chronic hepatitis C, highlighting potential autoimmune side effects of interferon-based therapies.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

This study presents a case of treatment-resistant alopecia universalis that successfully responded to a combination of tofacitinib and oral minoxidil, highlighting a potential therapeutic approach for challenging cases of alopecia areata.

This review suggests that 308 nm excimer therapy may offer a well-tolerated non-pharmacologic option for alopecia areata, with more limited evidence for its effectiveness in lichen planopilaris and frontal fibrosing alopecia.

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.

This review examines various pharmacological options for managing alopecia areata, highlighting the effectiveness of corticosteroids for mild to moderate cases and promising results from JAK inhibitors like baricitinib for more severe forms, with additional benefits from minoxidil and potential from other treatments.

This study reports that topical ruxolitinib failed to induce hair growth in a 66-year-old patient with alopecia areata, highlighting the need to explore factors affecting treatment response and compare topical vs oral administration outcomes.

In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.

This study found that tofacitinib effectively promoted hair regrowth in Asian patients with severe alopecia areata, with 74.3% showing a clinical response.

This retrospective study observed that switching from tofacitinib to baricitinib improved hair growth in patients with alopecia areata, particularly for previous non-responders, and noted fewer side effects with baricitinib.

This article reviews treatments for alopecia areata, including corticosteroids and other immunomodulators, and reports no new experimental findings.

This source reviews alopecia areata, highlighting its epidemiology, immune-related causes, diagnostic methods, and the shift in treatment with JAK inhibitors like baricitinib and ritlecitinib, marking the first disease-modifying options for this hair loss condition.

In this review, researchers explore evidence showing that JAK inhibitors, particularly baricitinib and deuruxolitinib, are effective in promoting hair regrowth in severe alopecia areata while maintaining acceptable safety profiles, though long-term data remains scarce.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

This source highlights that alopecia areata is a complex autoimmune disorder leading to patchy, nonscarring hair loss with variable treatment responses, reflecting unmet clinical needs. Advances in genetic research are improving understanding, yet current treatments often lead to persistent relapses.